Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.

Chinese medical journal - 5 Mar 2017

Ye Qing, Qi Fan, Bian Li, Zhang Shao-Hua, Wang Tao, Jiang Ze-Fei

Abstract excerpt

BACKGROUND: The addition of anti-human epidermal growth factor receptor 2 (HER2)-targeted drugs, such as trastuzumab, lapatinib, and trastuzumab emtansine (T-DM1), to chemotherapy significantly improved prognosis of HER2-positive breast cancer patients. However, it was confused that metastatic patients vary in the response of targeted drug. Therefore, methods of accurately predicting drug response were really...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cadherins
Share to Chromogranins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to GTP-Binding Protein alpha Subunits, Gs

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, ErbB-2

Share to Receptor, Notch1

Source

Open in PubMed Open full text

Identifiers

PMID: 28229982
DOI: 10.4103/0366-6999.200542
PMCID: PMC5339924

Genes

CDH1
EGFR
GNAS
HRAS
KIT
MLH1
NOTCH1
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.PMID 28229982Read ↗

Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer PatientsSemantic proximity Read ↗

Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer Patients.Semantic proximity Read ↗

Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer.Semantic proximity Read ↗

Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance.Semantic proximity Read ↗

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancerSemantic proximity Read ↗

Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.Semantic proximity Read ↗

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read ↗

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.Semantic proximity Read ↗

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysisSemantic proximity Read ↗

Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.Semantic proximity Read ↗

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.